BioSpace News Archive

Codagenix Inc. today announced interim Phase 1 data indicating induction of T cell immunity against highly-conserved antigens of the SARS-CoV-2 Omicron variant following two doses of its intranasal vaccine, CoviLiv (previously called Covi-Vac).

Virios Therapeutics, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2021.

Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the publication of an article entitled “ BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study ” in the prestigious American Journal of Respiratory and Critical Care Medicine – which has an impact factor of 21.4.

Cullinan Oncology, Inc. today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2021.

InMed Pharmaceuticals Inc. today announces that its Chief Financial Officer, Mr. Bruce Colwill, will be retiring and will be stepping down from his position at the Company effective March 31, 2022.

Integer Holdings Corporation, a leading medical device outsource manufacturer, announced that Bill R. Sanford will be retiring as Chair of the Integer Board of Directors at the conclusion of the Company’s 2022 annual meeting of stockholders, which is scheduled to be held on May 18, 2022.

Aquestive Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AQST-109, the first and only orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions.

Seegene Inc. (KQ 096530), South Korea’s leading molecular diagnostics company, today announced the appointment of Glen Hansen, Ph.D., D(ABMM), FCCM, as the Head of Scientific and Medical Affairs of its United States subsidiary, Seegene Technologies.

Amyris, Inc., a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform announced that management will participate in a fireside chat at the Jefferies Virtual Synthetic Biology Week on Wednesday, March 23, 2022, at 2:00 pm ET.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), today announced that Peginterferon Lambda (Lambda) significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits greater than six hours by 50% (primary endpoint) and death by 60% in the Phase 3 TOGETHER study.